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PURPOSE. To determine the relationship between cone deacti-
vation kinetics in patients with the enhanced S cone syndrome
(ESCS) caused by mutations in NR2E3 and the immunoreactiv-
ity to G-protein–coupled receptor kinase 1 (GRK1) and GRK7.
METHODS. Electroretinogram (ERG) photoresponses were used
to investigate activation kinetics of cones with a model of cone
phototransduction. Deactivation kinetics of cones after bright
flashes was quantified with a paired-flash ERG paradigm. Im-
munocytochemistry was performed with antibodies against
cone opsins and kinases GRK1 and GRK7 in postmortem nor-
mal and ESCS retinal tissue.
RESULTS. Activation kinetics of long/middle-wavelength–sensi-
tive (L/M) cone-mediated responses in patients with ESCS were
similar to those of normal L/M cones. Activation kinetics of
ESCS short-wavelength–sensitive (S) cones, when compared
with normal L/M cone responses evoked by the same stimulus,
were slower by an amount consistent with the expected dif-
ferences in spectral sensitivities. After bright flashes chosen to
evoke identical activation kinetics, ESCS S cones deactivated
much more slowly than ESCS or normal L/M cones. Normal
human retina revealed strongly labeled cone outer segments
with anti-GRK1 and anti-GRK7. In an ESCS retina, outer seg-
ments positive for L/M opsin were strongly labeled with anti-
GRK1, whereas outer segments positive for S opsin showed no
detectable GRK1 reactivity. GRK7 labeling was absent in all
photoreceptors of the ESCS retina.
CONCLUSIONS. The cone-dominant human retina resulting from
NR2E3 mutations affords greater understanding of the physio-
logical roles of GRK1 and GRK7 in human cone photo-
receptors. Normal deactivation kinetics in human L/M cones
can occur without GRK7 when GRK1 is present in ESCS, but
does not occur when GRK7 is present but GRK1 is deficient
in Oguchi disease. Lack of both GRK1 and GRK7 in S cones
of patients with ESCS results in a more pronounced abnor-
mality in deactivation kinetics and suggests the existence of
partial compensation by either GRK when the other is
deficient. (Invest Ophthalmol Vis Sci. 2003;44:1268–1274)
DOI:10.1167/iovs.02-0494
Most environmental stimuli, such as light and odor, lead toa response in sensory neurons by activating G-protein–
coupled receptors (GPCRs), which form the largest known
family of signal-transducing proteins. Phosphorylation by
G-protein– coupled receptor kinases (GRK) initiates timely
termination of GPCR signaling by homologous desensitiza-
tion targeted specifically to activated receptors.1 Photore-
ceptors in the human retina are sensory neurons where
activation of GPCR followed by quick deactivation results in
a highly reproducible signal, the photoresponse.2 Unlike in
rod photoreceptor cells and unlike in most other mammals,
human (and monkey) cone photoreceptors express two
GRKs, GRK1 and GRK7.3,4 The relative contributions of
these two molecules to human cone cell deactivation are
currently unknown.
We have sought understanding of cone photoreceptor func-
tion in humans through naturally occurring, molecularly de-
fined human disease. Abnormally slow cone deactivation kinet-
ics in Oguchi disease caused by a homozygous null mutation in
the GRK1 gene has provided evidence that GRK1 contributes
to human cone function.5 Grk1/ mice also show slowed
kinetics of cone deactivation. The extent of the abnormality in
mice appears more exaggerated than in humans.6 Contribution
of phosphorylation by GRK7 expressed in human, but not in
mouse, cones has been proposed to explain the apparent
interspecies differences in phenotype resulting from a lack of
functional GRK1.3,4 In the current work, we took advantage of
the large ERG signals originating from cone-dominant human
retinas in patients with the enhanced S cone syndrome (ESCS)
to further investigate cone deactivation. Mutations in NR2E3
cause ESCS, in which an abnormality in cell-fate determination
leads to a photoreceptor mosaic dominated by cones express-
ing short-wavelength–sensitive (S) opsin, and fewer cones ex-
pressing long/middle-wavelength-sensitive (L/M) opsin.7–13
Postmortem human retinal tissue from a patient with ESCS
gave us the rare opportunity to relate the expression of GRK1
and GRK7 to physiology in cones.
METHODS
Subjects
Normal subjects and 11 patients with ESCS caused by NR2E3 muta-
tions were included in the study.11–13 Previously published5 data from
a patient with Oguchi disease caused by a homozygous null mutation
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in the GRK1 gene were reanalyzed and presented as a comparison to
the ESCS results. Ten of 11 patients with ESCS contributed to different
aspects of the electrophysiological results (not all patients had all tests;
the number undergoing each test is specified later). The eye donor had
nonrecordable ERGs, but her psychophysical results were typical of
those with ESCS.13 Informed consent was obtained from subjects after
explanation of the procedures. All studies conformed to institutional
guidelines and the Declaration of Helsinki. Student’s t-test was used for
testing the significance of the difference of means.
Electroretinography
The magnitude of the photoreceptor dark-current immediately before
the presentation of a light flash and the initial kinetics of its suppres-
sion can be estimated in vivo by recording the leading edge (15 ms)
of ERG photoresponses evoked with high-energy stimuli14 and analyz-
ing it with biochemically based quantitative models.15 The magnitude
of the dark current at longer (15 ms) times, including the kinetics of
the restoration of the dark current, can be estimated in vivo with the
paired-flash paradigm, by using a test flash and a probe flash.16–18 The
details of our methods for recording and analyzing single- and paired-
flash ERG photoresponses evoked with high-energy (saturating) stimuli
in human subjects have been published.5,9,19–24
In the current set of experiments, full-field (ganzfeld) flash (1 ms)
stimuli were presented, and the resultant ERG photoresponses were
recorded with unipolar Burian-Allen (Hansen Ophthalmics, Iowa City,
IA) contact lens electrodes (referenced to the forehead) and a com-
puterized ERG apparatus (Pathfinder II; Nicolet Instruments Corp.,
Madison, WI). In most experiments, recording bandwidth was 1 kHz,
and waveforms were digitized at 2.5 kHz. In the remaining experi-
ments, higher bandwidths and higher sampling frequencies were used.
In normal subjects, patients with ESCS, and the patient with Oguchi
disease, single-flash ERG photoresponse families were recorded with
red (Wratten 26 filter; Eastman Kodak Co., Rochester, NY) flashes
(most subjects had series from 2.2–4.1 log troland-seconds [td  s];
some subjects had 3.6 and 4.1 log td  s) under light adaptation (white,
3.2 log td). Current evidence suggests that these responses are domi-
nated by L/M cone activity.5,9,19,23 In patients with ESCS, additional
photoresponse families were recorded with violet (Wratten 98 filter;
1.0–2.5 log td  s) or white (3.8–5.1 log td  s) flash stimuli under light
adaptation (white, 3.2 log td). Responses evoked by violet and white
flashes in ESCS are dominated by S cone activity.7–9,11 To date, we have
been unable to record an unequivocal S cone–mediated component
within the leading edge of photoresponses in normal subjects9,11 or in
pigs with an S cone density higher than that in normal humans.24
Leading edges (10 ms) of all photoresponse families were fit with the
alternative model of cone phototransduction activation19,23 by allow-
ing two free parameters of this model: maximum amplitude (Rmax) and
sensitivity () to change. Other parameters were fixed at values pre-
viously published for normal subjects.19,23 Flash luminances were
measured with a calibrated photometer (model IL1700; International
Light, Newburyport, MA).
Paired-flash ERG photoresponses were used to estimate the kinetics
of cone deactivation under light-adaptation (white, 3.2 log td). In
normal subjects and in the patient with Oguchi disease, a white (4.1
log td  s) test flash was followed by a red (4.1 log td  s) probe flash for
a range of interstimulus intervals (100–400 ms). In patients with ESCS
L/M cone deactivation was estimated with red test and red probe
flashes (both 4.1 log td  s), and S cone deactivation was estimated with
white test and white probe stimuli. Based on pilot experiments esti-
mating differences in sensitivity of responses dominated by L/M and S
cones in ESCS (described later), the test and probe flashes for S cone
deactivation were chosen to be 5.1 log td  s. Amplitude of the photo-
response evoked by each probe was measured at a fixed time (10 ms),
and deactivation kinetics was quantified by fitting an S-shaped function
of the form R(t)/R0  1/{1  exp[ (t  t1⁄2)/]}, where R(t) is the
amplitude of the response evoked by the probe presented at time t
after the test flash, R0 is the amplitude of the probe-alone response, t1⁄2
is the half-recovery time, and  is a parameter that defines the rate of
recovery.25
Estimation of Isomerizations in Normal Cones
For the interpretation of the results of the current work, we assume
that a given number of isomerizations in human cones produce a
stereotypical photoresponse with invariant kinetics independent of
cone type. This assumption is based on evidence from single cells
stimulated with dim flashes in primate L, M, and S cones.26 Because of
the lack of evidence to the contrary, we parsimoniously assume that
the invariance also extends to the activation and deactivation phases of
saturating photoresponses in vivo. This assumption allows us to com-
pare the S cone–mediated responses in patients with ESCS to L/M-
cone–mediated responses in normal subjects and patients, as long as
the responses are evoked by an equal number of isomerizations in
respective cone types.
The relative effectiveness of an external stimulus in causing isomer-
ization in different cone types can be estimated with the spectral
energy distribution of the stimulus, spectral sensitivity, quantum effi-
ciency, peak optical density and light-funneling factor for each photo-
receptor type, and transmission spectra of preretinal filters. We used
recent estimates of relative spectral sensitivity of S, L, and M cones27,28
and assumed equal quantum efficiency.29 For peak optical densities,
we used 0.15 for peripheral S cones and 0.3 for peripheral L and M
cones.27,28 We assumed that light-funneling is proportional to the axial
taper of the inner segment cross-sectional area. We estimated this ratio
to be 1.6 times greater for peripheral L and M cones than for S cones,
based on published mean diameters.30,31 We used a recent estimate of
average lens-density spectrum28 as the most significant preretinal filter
for stimulating the peripheral retina. Spectral energy distribution of the
flash (measured with a calibrated spectrometer model USB2000; Ocean
Optics, Dunedin, FL) was multiplied by the lens-transmission spectrum
and the sensitivity spectra of respective cone types and integrated with
respect to wavelength. Each integral was multiplied with the light-
transmission and funneling factors of respective cone types to arrive at
relative estimates of isomerization efficiency for the three cone types.
For the white flash used in the current work, the resultant estimate
shows 0.98 and 1.11 log unit lower isomerizations in S cones than in
M and L cones, respectively.
Considering a white flash of 1 cd  s/m2 integrated luminance has
been previously estimated to cause approximately 3000 isomerizations
per peripheral L/M cone when viewed by a normal human eye with a
dilated pupil,32–34 our relative isomerization efficiency can be used to
estimate an absolute value of approximately 300 isomerizations per
peripheral S cone per 1 cd  s/m2 full-field white flash viewed by a
dilated pupil. In terms of the stimuli used in the current work, the 5.1
log td  s white flash would result in 8  105 isomerizations per S cone,
which would be matched by 4.1 log td  s flashes in L/M cones. Because
of the small (10%) amplitudes expected, we disregarded the contri-
bution of L/M cones to white flashes, the contribution of S cones to red
flashes in ESCS, and the contribution of S cones to red or white flashes
in the patient with Oguchi disease and normal subjects (see the Results
section).
Immunocytochemistry
Cryosections of three normal adult human retinas, one retina with
ESCS caused by NR2E3 mutations,13 and one retina with autosomal
dominant retinitis pigmentosa caused by the T17M mutation in rho-
dopsin35 were processed for immunofluorescence, as described pre-
viously.36 Primary antibodies were mouse anti-GRK1 (1:400, Affinity
Bioreagents, Inc., Golden, CO), rabbit anti-GRK7 (1:253), rabbit anti-
L/M cone opsin (1:500, UW-161; John Saari, University of Washington,
Seattle, WA); rabbit anti-S cone opsin (1:5000; JH 455; Jeremy Nathans,
Johns Hopkins University, Baltimore, MD), and mouse anti-S cone
opsin (1:1000, OS-2; Ágoston Szel, Semmelweis University Medical
School, Budapest, Hungary). Cell nuclei were stained blue (T0-PRO-3;
Molecular Probes, Eugene, OR). Sections were examined by epifluo-
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Leading edges of an ERG photoresponse family recorded under
light adaptation in a representative normal human subject
demonstrated the electrical activity that is believed to be dom-
inated by simultaneous activation of L/M cones across the
retina (Fig. 1A, top). The model of cone phototransduction
activation, fit as an ensemble, quantitatively describes the re-
sponse family with two parameters, Rmax (82 V) and  (2.28
log td1  s3), which relate to the outer segment membrane
area and the amplification during activation, respectively, av-
eraged across the retina.37 Statistics of these parameters in a
group of normal subjects have been previously defined
(mean  95% CI, Rmax  85.3  4.3 V,   2.26  0.07 log
td1  s3, n  16). In a representative ESCS patient (Fig. 1A,
middle) ERG photoresponses evoked by red flashes appear
qualitatively similar to normal results, although of smaller am-
plitude. Using spectrally distinct stimuli, previous work has
demonstrated that these responses are dominated by the activ-
ity of the L/M cone system in patients with ESCS.7–11 Not
unexpectedly, the model of cone phototransduction describes
the leading edges of the responses. Patients with ESCS showed
a significantly (P  0.001) abnormal Rmax (37.4  8.8 V, n 
8); but  parameter (2.20  0.11 log phot td1  s3, n  8)
was not significantly different from normal (P  0.33). These
results would be consistent with an abnormally reduced num-
ber of L/M cones (or shortened L/M cone outer segments) in
ESCS retinas containing normal molecular components neces-
sary for signal amplification during activation.
ERG photoresponses evoked with violet or white stimuli
under light adaptation in patients with ESCS can be much
larger in amplitude than normal responses, albeit showing
similar kinetics (Fig. 1A, bottom). Leading edges (10 ms) of
these responses were well described by the model of cone
phototransduction activation. The Rmax of white-flash re-
sponses was 368 V (94 V, n  6) and that of violet
responses was 356  58 V, n  6). Their similarity was
FIGURE 1. Activation and deactiva-
tion kinetics of phototransduction in
human patients with ESCS. (A) Lead-
ing edges of ERG photoresponse fam-
ily (4.1–2.2 log td  s red flashes)
dominated by L/M cone activity in a
normal subject (top) and in ESCS
(middle) showed similarity of activa-
tion kinetics. Further photoresponses
in the same subject (bottom) illus-
trated the higher stimulus energies
(traces, 5.1–2.5 log td  s white
flashes) or shorter wavelengths (sym-
bols and traces, 2.5–1.9 log td  s vi-
olet flashes) needed to equate activa-
tion kinetics of S- and L/M-cone–
dominated responses. All waveforms
recorded on a 3.2-log td white back-
ground. Model of cone phototrans-
duction activation (gray lines) was
fit to each series as an ensemble
(Rmax 82, 39, and 302 V,   2.3,
2.1, and 1.1 log td1  s3, respec-
tively for top, middle, and bottom).
(B) Representative waveforms re-
corded with a paired-flash paradigm
in which the test flash is at time 0
and the probe flash is at the time
indicated with the arrow. White test
flashes were 4.1 log td  s in the nor-
mal subject and 5.1 log td  s in the
patient with ESCS. The probe flashes
were red (4.1 log td  s) in the normal
subject and white (5.1 log td  s) in
the patient. All waveforms recorded
on a 3.2-log td white background.
(C) Activation kinetics of leading
edges evoked by test flashes aver-
aged over all trials for each subject,
normalized to amplitude at 10 ms,
and averaged across subjects
(mean  95% CI shown at 1-ms in-
tervals for clarity of presentation).
Previously published data from a pa-
tient with Oguchi disease were rean-
alyzed and shown for comparison. Symbols are described in (D). (D) Normalized amplitude of the response evoked by probe flashes (4.1 log td  s
red for L/M cones, 5.1 log td  s white for S cones) as a function of the time interval between test and probe flashes. Photoresponse amplitudes
evoked by probe flashes with preceding test flashes were normalized by response amplitudes evoked by probe only. Results shown with amplitudes
measured at 10 ms. Results are essentially identical when amplitudes are measured at 8 or 12 ms. Error bars represent 95% CI. Smooth gray lines:
S-shaped curves fit by eye.
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consistent with previous work suggesting that both white and
violet flash responses are dominated by the activity of the
S cone system in patients with ESCS.7–11 The ratio of Rmax in
responses evoked by white flash to that evoked by red stimuli
was 9.29  1.15 (n  6), which in turn was consistent with the
approximately 10:1 ratio of S:L/M photoreceptor cell density
found in an ESCS eye.13
The sensitivity parameter of white flash photoresponses in
patients with ESCS (  1.08  0.17 log phot td1  s3, n 
6) was significantly (P  0.001) different from normal photo-
responses. The difference in apparent sensitivities of S and L/M
cones in patients with ESCS compared favorably with that
expected from a theoretical analysis of normal S and L/M cones
(see the Methods section).
Deactivation Kinetics
The deactivation kinetics of normal human L/M-cone photore-
sponses was demonstrated with waveforms evoked by the
paired-flash paradigm, in which a white test flash is followed at
fixed times with a red probe flash (Fig. 1B, left panel). The
leading edge amplitude of the probe response was approxi-
mately half of the probe-alone response by 120 ms and fully
recovered between 140 and 200 ms. Some normal subjects
showed probe-response amplitudes larger than probe-alone
responses over the interval 150 to 300 ms. Other subjects did
not show this overshoot. The early phase of the deactivation
function from a group of normal subjects is fit with   12 ms
and t1⁄2 110 ms (Fig. 1D).
Deactivation in ESCS cones was studied with the test flashes
chosen to evoke activation phases identical with the test
flashes used to determine deactivation kinetics in normal hu-
man L/M cones. For ESCS-L/M cones, red test flashes were
used, and for ESCS-S cones, white test flashes were used (Fig.
1C). ESCS-L/M cones showed normal deactivation phase kinet-
ics, although in this sample, they appeared not to have the
overshoot seen in some normal subjects (Fig. 1D). The deacti-
vation kinetics of ESCS-S cones was much slower than normal
and ESCS L/M cones (Figs. 1B, 1D;   85 ms, t1⁄2 300 ms),
although the activation phase to the test flash was matched in
kinetics to normal and ESCS L/M cones (Fig. 1C) and thus was
assumed to have resulted in the same number of isomeriza-
tions.
Abnormally delayed cone deactivation kinetics has been
reported to date in only one other human retinopathy, Oguchi
disease due to a null mutation in the GRK1 gene.5 We reana-
lyzed our previously published data with current methods and
present the activation and deactivation kinetics for comparison
with the current results (Figs. 1C, 1D). With the test flash used,
L/M-cone–dominated responses in the patient with Oguchi
disease showed activation kinetics similar to those in normal
subjects (Fig. 1C), but the deactivation was delayed (Fig. 1D;
  13 ms, t1⁄2  135 ms). Specifically, recovery of amplitude at
probe times of 100 and 120 ms after the test flash falls outside
the 95% CI of a group of normal results.
GRK1/7 Expression
We performed immunocytochemistry to document GRK1 and
GRK7 in photoreceptors of a patient with ESCS. Normal adult
human retina sections showed labeling of all rod outer seg-
ments with anti-GRK1 (Fig. 2A–C), and of all cone outer seg-
ments with both anti-GRK1 and anti-GRK7 (Figs. 2A–F). The
cones in the ESCS retina were present in layers of rather
uniform thickness, and there was no scalloping of the outer
nuclear layer.38 The cone outer segments ranged from short to
absent. ESCS outer segments expressing L/M opsin showed
strong GRK1 labeling but no GRK7 labeling. Outer segments
expressing S opsin showed no immunoreactivity for GRK1 or
GRK7 (Figs. 2G–L). To rule out downregulation of GRK1 and
GRK7 expression secondary to a degenerative process, we also
investigated a human retina that was previously shown to lack
expression of some cytoplasmic proteins.39 The retina with
retinitis pigmentosa due to a mutation in the rhodopsin gene
showed labeling of all rod outer segments with anti-GRK1 (Fig.
2M) and of all cone outer segments with both anti-GRK1 and
anti-GRK7 (Figs. 2M, 2N).
DISCUSSION
Colocalization of two members of the GRK family in human
cone photoreceptors led to the hypothesis of shared enzymatic
activity by GRK1 and GRK7 in phosphorylating photoisomer-
ized cone opsins, thus initiating deactivation.3,4 We were able
to test this hypothesis in vivo in cone-dominant retinas of
patients with ESCS, in a patient with Oguchi disease, and in
normal subjects and correlate the pathophysiology to GRK1
and GRK7 expression in retinas from donor eyes. In electro-
physiological experiments, our stimuli evoked a-waves with
saturated amplitudes (ERG photoresponses) dominated by L/M
cones in the patient with Oguchi disease and normal subjects,
and by L/M or S cones (depending on stimulus color) in
patients with ESCS. It is well accepted that kinetics of activa-
tion, duration of saturation, and kinetics of deactivation result-
ing from a bright flash in a given photoreceptor type depend
strongly on the number of visual pigment molecules isomer-
ized. Specifically, an increase in the number of isomerizations
results in faster activation, longer saturation, and slower deac-
tivation kinetics.16–18,26 Thus, to be able to compare deactiva-
tion kinetics in the four different photoreceptor types, we had
to consider possible differences in their sensitivity to external
light stimuli. We used a model of cone phototransduction
activation and determined that L/M cone dominated ERG pho-
toresponse sensitivities in patients with ESCS or Oguchi disease
were normal. We therefore assumed that a given flash would
produce the same number of isomerizations in the three
groups of L/M cones. Photoresponses of ESCS S cones were
approximately 1 log unit less sensitive than normal L/M cones.
This was consistent with the difference expected between
normal S and L/M cones, suggesting that the anatomy and
phototransduction activation reactions of ESCS S cones could
not be dramatically different from normal S cones. A direct test
of this hypothesis would require better definition of the anat-
omy of ESCS S cones and the physiology of normal S cones. For
the current work, we empirically chose test flash intensities
that would be expected to result in an equal number of isomer-
izations in ESCS S and L/M cones during deactivation experi-
ments.
Deactivation of L/M cones in patients with ESCS showed
normal kinetics. Unexpectedly, L/M cones from the ESCS retina
showed no detectable GRK7 immunoreactivity, although they
were positive for GRK1. Deactivation of L/M cones in Oguchi
disease due to a null mutation in the GRK1 gene, however, was
abnormally slow. Although direct evidence is lacking, it is
reasonable to assume that the retina in Oguchi disease does not
have functional GRK1 but does possess GRK7. Results from
patients with ESCS or Oguchi disease, taken together, argue
against a predominant physiological role for GRK7-mediated
phosphorylation in human L/M cones. In contrast, GRK1-me-
diated phosphorylation appears necessary for the attainment of
the normal rate of deactivation. The possibility of both GRKs
contributing to human cone deactivation is not inconsistent
with our results. Under this scenario, the observed absence of
physiological abnormality in L/M cones in ESCS could be due to
upregulation of GRK1 to compensate for the lack of GRK7.
Upregulation of GRK7 in Oguchi disease would then not be as
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physiologically effective and would result in the abnormal
recovery detectable with our methods.
In terms of GRK1 and GRK7 expression, ESCS L/M cones
are similar to normal mouse and rat cones,3,4 in that they all
have no GRK7 and have only GRK1. Activation and deacti-
vation kinetics of normal mouse cones have been reported,
using a paired-flash ERG method similar to that used in the
current work.6,40 For test flashes that produce activation
kinetics approximately 1.5 ms slower than the test flashes
used in the current work, deactivation kinetics of mice are
much slower than ESCS (and normal) L/M cones.6,40 It is
reasonable to assume that brighter test flashes in mice that
evoke responses with a time course similar to the current
experiments would result in even slower deactivation kinet-
ics and even larger differences between ESCS L/M cones and
normal mouse cones. This argument leads to the speculation
that major differences between human and mouse (in addi-
tion to expression of GRK) must exist in molecular compo-
nents contributing to cone recovery. Further studies isolat-
ing the activation and deactivation components of mouse
UV and M cones would provide a better interspecies com-
parison.40 A similar line of reasoning can be made for GRK1-
associated Oguchi L/M cones and normal cones in the dog
and pig—that is, that they all have no functional GRK1 and
presumably have only GRK7 contributing to phosphoryla-
tion of activated cone pigments.3 A comparison of deactiva-
tion kinetics in dogs and pigs with that found in the patient
with Oguchi disease would be of strong interest.
Deactivation kinetics of ESCS S cones were much slower
than L/M cones in normal, ESCS or Oguchi retinas. ESCS S
cones unexpectedly showed no immunoreactivity to both
GRK1 and GRK7. Assumption of the stereotypy of phototrans-
FIGURE 2. Immunocytochemistry of
human retinas labeled with anti-
GRK1 and -GRK7. Cell nuclei have
been stained (blue) with T0-PRO-3.
The layer of cells across the bottom
of (F) and (L) is the retinal pigment
epithelium (R) that is filled with
autofluorescent lipofuscin granules.
(A) Normal human retina labeled
with anti-GRK1 (red). Note specific
labeling of all rod (✽) and cone (ar-
rowheads) outer segments. (B) Same
field as (A) labeled with anti-L/M
cone opsin (green). Note labeling of
most cone outer segments (arrow-
heads). (C) Composite of (A) and (B)
showing that most cone outer seg-
ments (gold) were positive for both
GRK1 and L/M-cone opsin. One S
cone outer segment (red, arrow-
head) was positive for GRK1 but
negative for L/M cone opsin. (✽) Rod
outer segments. (D) Normal human
retina labeled with anti-GRK7 (red).
Note labeling of all cone outer seg-
ments. (E) Same field as in (D), la-
beled with anti-S cone opsin. (F)
Composite of (D) and (E) showing
two S cone outer segments (gold,
arrowheads) positive for GRK7. The
L/M-cone outer segments were posi-
tive for GRK7 (red) but negative for S
cone opsin. One S cone inner seg-
ment (middle, green) was positive
for S cone opsin, but its outer seg-
ment was not in the plane of section.
(G) ESCS retina labeled with anti-
GRK1 (red). Several cone outer seg-
ments were GRK1 positive. (H) Same
field as in (G). Several cone outer
segments were labeled with anti-L/M
cone opsin (green). (I) Composite of
(G) and (H). Note stronger GRK1 la-
beling of L/M cone outer segments
(arrowheads) than of most of the
cone outer segments that are S cone
opsin positive (see K). (J) ESCS ret-
ina labeled with anti-GRK7 (red).
Note absence of outer segment label-
ing. (K) Same field as in (J) labeled
with anti-S cone opsin (green). Most
outer segments were S cone opsin positive. (L) Composite of (J) and (K) showing ESCS retina labeled with anti-GRK7 (red) and anti-S cone opsin
(green). Note heavy labeling of most of the cone outer segments with anti-S cone opsin (green). No outer segments were GRK7 positive. (M)
Human retina with retinitis pigmentosa caused by a mutation in the rhodopsin gene. All rod (✽) and cone (arrowheads) outer segments were
positive for GRK1 (red). (N) The human retina in (M) labeled with anti-GRK7 (red). Note that all cone outer segments (arrowheads) were GRK7
positive. Bar, 100 m.
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duction in all human cones allows the parsimonious conclu-
sion that the absence of both GRK1 and GRK7 causes a greater
degree of abnormality in cone deactivation than that caused by
the deficiency of either GRK alone. This in turn is consistent
with the speculation that both GRKs contribute to deactivation
in human cones. This hypothesis appears more tenable than
the alternative that neither GRK1 nor GRK7 contributes signif-
icantly to human cone deactivation and that the slow deacti-
vation observed in Oguchi L/M cones and ESCS S cones is due
to abnormalities in other components of the cone deactivation
process. It is important to note that, ideally, the pathophysiol-
ogy in ESCS S cones should be interpreted by direct compari-
son to normal human S cones. However, estimates of activation
and deactivation in normal S cones have not been recordable to
date in humans9,11 or in animals known to have a higher
density of S cones.24
One of the major physiological differences between cones
and rods is the dramatically faster recovery observed in cones
after flashes of light.41 The existence of a cone-specific kinase,
such as GRK7, could contribute significantly to this fast recov-
ery.3,4,41,42 Our in vivo results suggest that human cones with-
out either GRK1 or GRK7 or both still recover much faster than
normal human rods (t1⁄2  0.3 seconds for cones compared
with t1⁄2  10 seconds for rods16) when matched by the esti-
mated number of isomerizations resulting from the test flash.
Assuming that results from Oguchi and ESCS cones can be
extrapolated to normal human cones, we can speculate that
there are molecular components, other than GRK1/7 phos-
phorylation, contributing significantly to the human cone re-
covery. Among the candidates are those involved in the deac-
tivation of the activated cone pigment (for example, cone
arrestin43), the activated transducin (for example, RGS9-144),
and cone pigment regeneration. Future studies in naturally
occurring molecularly defined human diseases could be useful
in furthering our understanding in this area. For example,
measurement of cone deactivation kinetics in patients with
fundus albipunctatus due to null mutations in RDH5, who
show a dramatic slowing in cone pigment regeneration,22
would allow estimation of the contribution of cone pigment
regeneration to cone deactivation.
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